GlassScriptPhysician profile
Anita Misra
NPI 1750381562
$9,073.44
in general payments reported to CMS, 2019-2025
44 companies · $693 in 2025
The $693 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,861 · 2020: $1,798 · 2021: $1,781 · 2022: $1,325 · 2023: $962 · 2024: $653 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,308.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,296.39 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,111.17 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novo Nordisk INC | $1,018.76 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $575.95 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $522.13 | 2019-2022 | |
| Lilly USA, LLC | $468.01 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $457.60 | 2019-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $346.53 | 2022-2025 | |
| Amarin Pharma, INC. | $345.72 | 2019-2022 | |
| Abbott Laboratories | $340.99 | 2021-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $275.10 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $261.26 | 2019-2023 | |
| Daiichi Sankyo INC. | $153.68 | 2020-2025 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.67 | 2019-2022 | |
| Dexcom, INC. | $144.59 | 2023-2025 | Dexcom G6 Transmitter |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anita Misra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.